Opinion statement
Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Jeannon JP, Calman F, Gleeson M, et al. Management of advanced parotid cancer: a systematic review. Eur J Surg Oncol. 2009; 35: 908–915.
Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008; 35: 309–319.
Lee YYP, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumors. Eur J Radiol. 2008;66:419–36.
Shah GV. MR imaging of the salivary glands. Magn Reson Imaging Clin N Am. 2002;10:631–62.
Keyes JW, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99–102.
Cohen EG, Patel SG, Lin O, et al. Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Arch Otolaryngol Head Neck Surg. 2004; 130: 773–778.
Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:546–50.
Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J Pathol. 1994;173:13–21.
Luukkaa H, Klemi P, Leivo I, et al. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006;45:669–75.
Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope. 1997;107:531–6.
Miyabe S, Okabe M, Nagatsuka H, et al. Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg. 2009;67(7):1432–41.
Hoyek-Gebeily J, Nehme E, Aftimos G, et al. Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series. J Med Liban. 2007;55:83–8.
Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumours. J Oral Path Med. 1997;26:217–23.
Kiyoshima T, Shima K, Kobayashi I, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol. 2001;37:315–7.
Williams MD, Roberts DB, Lies MS, et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Can Res. 2010; 16: 2266–2274.
Seethala RR, Dacic S, Cieply K, et al. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106–21.
Okabe M, Miyabe S, Nagatsuka H, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Can Res. 2006;12:3902–7.
Okumura Y, Miyabe S, Nakayama T, et al. Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma. Histopathology. 2011;59:90–7.
Ben-Izhak O, Akrish S, Gan S, Nagler RM. p27 and salivary cancer. Cancer Immunol Immunother. 2009;58:469–73.
Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007; 69 Suppl: S52–S55. Excellent review of the role of radiotherapy for salivary cancer summarizing evidence concerning major issues.
Alterio D, Jereczek-Fossa BA, Griseri M, et al. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years experience at the European Institute of Oncology. Tumori. 2011;97:328–34.
Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45: 574–578.
Mariano FV, da Silva SD, Chulan TC, et al. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas. Int J Oral Maxillofac Surg. 2011;40:504–9.
Westra WH, Kronz JD, Eisele DW. The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital. Head Neck 2002; 24: 684–693.
Kobayashi K, Nakao K, Yoshida M, et al. Recurrent cancer of the parotid gland: how well does surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec. 2009;71:239–43.
Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary malignancies. Radiother Oncol. 2010; 95: 308–311. Paper provides evidence of the relative safety of reirradiation protocols in recurrent salivary cancer.
Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011; 12: 815–824.
Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 905–911.
Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer. 2010;116:362–8.
Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7:1–6.
Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase 2 study. Oral Oncol. 2003;39:724–7.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gillespie, M.B., Albergotti, W.G. & Eisele, D.W. Recurrent Salivary Gland Cancer. Curr. Treat. Options in Oncol. 13, 58–70 (2012). https://doi.org/10.1007/s11864-011-0174-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-011-0174-0